Evidence map›Paper›PMID 36614334›Full record

ArticleInternational journal of molecular sciences2023

Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study.

Cristina Agliardi, Franca Rosa Guerini, Milena Zanzottera, Elisabetta Bolognesi, Silvia Picciolini, Domenico Caputo, Marco Rovaris, Maria Barbara Pasanisi, Mario Clerici

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Cristina AgliardiIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.ORCID 0000-0003-2022-3386
Franca Rosa GueriniIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.ORCID 0000-0001-9461-5927
Milena ZanzotteraIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
Elisabetta BolognesiIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.ORCID 0000-0001-5554-1697
Silvia PiccioliniIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.ORCID 0000-0002-7592-0253
Domenico CaputoIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
Marco RovarisIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
Maria Barbara PasanisiIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
Mario ClericiIRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
Don Carlo Gnocchi Foundation · ITUniversity of Milan · IT

Funding

Fondazione Alessandro e Vincenzo Negroni Prati MorosiniFondazione Romeo ed Enrica InvernizziGoverno Italiano: Ricerca Corrente
6 · The paper itself

Abstract

Approximately 15% of multiple sclerosis (MS) patients develop a progressive form of disease from onset; this condition (primary progressive-PP) MS is difficult to diagnose and treat, and is associated with a poor prognosis. Extracellular vesicles (EVs) of brain origin isolated from blood and their protein cargoes could function as a biomarker of pathological conditions. We verified whether MBP and MOG content in oligodendrocytes-derived EVs (ODEVs) could be biomarkers of MS and could help in the differential diagnosis of clinical MS phenotypes. A total of 136 individuals (7 clinically isolated syndrome (CIS), 18 PPMS, 49 relapsing remitting (RRMS)) and 70 matched healthy controls (HC) were enrolled. ODEVs were enriched from serum by immune-capture with anti-MOG antibody; MBP and MOG protein cargoes were measured by ELISA. MBP concentration in ODEVs was significantly increased in CIS (p < 0.001), RRMS (p < 0.001) and PPMS (p < 0.001) compared to HC and was correlated with disease severity measured by EDSS and MSSS. Notably, MBP concentration in ODEVs was also significantly augmented in PPMS compared to RRMS (p = 0.004) and CIS (p = 0.03). Logistic regression and ROC analyses confirmed these results. A minimally invasive blood test measuring the concentration of MBP in ODEVs is a promising tool that could facilitate MS diagnosis.

Indexed as

Extracellular VesiclesMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingMyelin Basic ProteinBiomarkersHumansMyelin-Oligodendrocyte GlycoproteinOligodendrogliaPilot ProjectsPrognosisBiomarkersMyelin Basic ProteinMyelin-Oligodendrocyte Glycoproteinbiomarkersexosomesextracellular vesiclesMBPMOGmultiple sclerosisoligodendrocytesprimary progressive multiple sclerosis

Identifiers

PMID36614334
PMCPMC9821098
OpenAlexW4313494380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.